Paper
0
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Authors
Published
Jan 16, 2013
Show more
Save
Tip0
TipSave
Abstract
For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development).
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.